Valeria Santini
0000-0002-5439-2172
University of Firenze
230 papers found
Refreshing results…
MOSAIC: An Artificial Intelligence–Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Treatment of Lower Risk Myelodysplastic Syndromes
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
Missing publications? Search for publications with a matching author name.